Act Two Investors LLC Purchases 6,930 Shares of Stryker Corporation $SYK

Act Two Investors LLC increased its position in Stryker Corporation (NYSE:SYK) by 13.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,147 shares of the medical technology company’s stock after purchasing an additional 6,930 shares during the period. Stryker accounts for 3.0% of Act Two Investors LLC’s portfolio, making the stock its 12th biggest position. Act Two Investors LLC’s holdings in Stryker were worth $15,738,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Danske Bank A S lifted its position in Stryker by 4.5% during the third quarter. Danske Bank A S now owns 218,478 shares of the medical technology company’s stock valued at $60,167,000 after buying an additional 9,421 shares during the period. Condor Capital Management grew its position in shares of Stryker by 1.9% in the 3rd quarter. Condor Capital Management now owns 11,002 shares of the medical technology company’s stock worth $3,030,000 after buying an additional 203 shares during the period. AlpenGlobal Capital LLC increased its stake in shares of Stryker by 1.0% in the 3rd quarter. AlpenGlobal Capital LLC now owns 6,217 shares of the medical technology company’s stock worth $1,712,000 after acquiring an additional 62 shares in the last quarter. Vista Capital Partners Inc. bought a new position in shares of Stryker in the 3rd quarter worth about $5,344,000. Finally, Moors & Cabot Inc. lifted its position in Stryker by 28.3% during the 3rd quarter. Moors & Cabot Inc. now owns 11,524 shares of the medical technology company’s stock valued at $3,174,000 after acquiring an additional 2,539 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 901,267 shares of company stock valued at $297,123,701 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 1.1%

Stryker stock traded down $3.34 during mid-day trading on Friday, reaching $309.05. The stock had a trading volume of 3,251,740 shares, compared to its average volume of 3,235,306. The company has a market capitalization of $117.65 billion, a price-to-earnings ratio of 32.91, a PEG ratio of 2.14 and a beta of 0.78. The company has a 50-day moving average price of $292.30 and a two-hundred day moving average price of $322.60. Stryker Corporation has a one year low of $267.00 and a one year high of $389.33. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period last year, the firm posted $3.19 earnings per share. On average, analysts expect that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SYK shares. Johnson Rice cut shares of Stryker to a “hold” rating in a report on Friday, October 30th. Robert W. Baird decreased their target price on shares of Stryker from $385.00 to $334.00 in a research note on Friday, October 30th. Jefferies Financial Group lowered their target price on shares of Stryker from $440.00 to $405.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Canaccord Genuity Group cut Stryker from a “buy” rating to a “hold” rating and dropped their price target for the stock from $385.00 to $300.00 in a research report on Friday, October 30th. Finally, JPMorgan Chase & Co. cut their price target on Stryker from $350.00 to $340.00 and set an “overweight” rating on the stock in a research note on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $342.19.

About Stryker

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.